Pharmaceuticals, Biotechnology and Life Sciences
REDWOOD CITY, Calif., July 11, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing…
— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential NDA Approval in…
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer…
SOUTH SAN FRANCISCO, Calif., July 11, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused…
Leuven, BELGIUM, Boston, MA, US – July 11, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next…
Figure 1 Change in FVC Over 12 Weeks in INTEGRIS-IPF; Mixed Model Repeat Measures Analysis – Intent to Treat Population…
Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7…
Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior…
Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis Investigational once-weekly efanesoctocog alfa prophylaxis…
FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a…